IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aesica to Expand HPAPI Capacity at Two Sites in U.K.

8:07 AM MST | February 7, 2012 | Deepti Ramesh

Aesica Pharmaceuticals (Newcastle upon Tyne, U.K.), a provider of active pharma ingredients (API), formulations, and custom synthesis, says it plans to upgrade its API manufacturing facilities, enabling it to manufacture high potency APIs (HPAPIs) at commercial scale. The expansion will be carried out at Aesica’s facilities at Cramlington and Queenborough in the U.K., the company tells CW. The new HPAPI investment "will be staggered and will amount to about $6.6 million over the next three years. HPAPI capabilities are a definite priority for us at...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa